Methods: We studied the effect a – tocopherol , g – tocopherol ,a – CEHC and g – CEHC on platelet adhesion and aggregation on collagen Type III surface at a shear rates of 100s-1 and 1000s-1 using whole blood in a parallel plate flow chamber. The effect of these drugs on platelet – platelet interactions was studied in a platelet aggregometer using convulxin as agonist. Activation of platelets by thrombin was studied in a flow cytometer by measuring platelet P-selectin expression.
Results: We saw that there was a significant decrease in platelet aggregation in the presence of g – tocopherol (50 µM) compared to control, but not a – tocopherol (50 µM). a - CEHC (5µM) and g – CEHC (5µM) have greater effect in reducing platelet aggregation than tocopherols at 1000 s-1. However, there was no effect of these drugs at 100 s-1. In the presence of L-NAME (L-Nitro arginine methyl ester), a potent inhibitor of nitric oxide production, there was less inhibition of platelet aggregation suggesting a role for eNOS (endothelial nitric oxide synthase). There was a dose dependent effect of g - tocopherol and CEHCs in inhibiting platelet aggregation.
Conclusions: a – tocopherol, also known as vitamin E, did not have any effect on reducing the platelet aggregation where as g – tocopherol and other metabolites of tocopherols significantly inhibit platelet aggregation. Flow chamber studies indicate that a – tocopherol and CEHCs partially effect platelet aggregation by eNOS pathway, but complete signaling mechanism needs to be investigated.
See more of #490 - Cardiovascular Systems in Health and Disease (15D16)
See more of Food, Pharmaceutical & Bioengineering Division
See more of The 2005 Annual Meeting (Cincinnati, OH)